HOWL Stock Risk & Deep Value Analysis

Werewolf Therapeutics Inc

Healthcare • Biotechnology

DVR Score

5.1

out of 10

Proceed with Caution

What You Need to Know About HOWL Stock

We analyzed Werewolf Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran HOWL through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive investment. Here's what we found.

Updated Mar 22, 2026•Run Fresh Analysis →

HOWL Risk Analysis & Red Flags

Risk Matrix

Overall

Aggressive investment

Financial

High

Market

High

Competitive

Medium

Execution

High

Regulatory

Medium

Upcoming Risk Events

📅
Failure to find suitable strategic alternatives
📅
Nasdaq delisting
📅
Further significant cash burn leading to additional dilution or bankruptcy
📅
Negative clinical data from remaining programs

Unlock HOWL Risk Analysis & Red Flags

Create a free account to see the full analysis

What Does Werewolf Therapeutics Inc (HOWL) Do?

Market Cap

$41.26M

Sector

Healthcare

Industry

Biotechnology

Employees

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Visit Werewolf Therapeutics Inc Website

Investment Thesis

Werewolf Therapeutics presents a highly speculative distressed asset play, where a 10x return within 3-5 years is contingent on a successful and favorable outcome from its strategic alternatives review (e.g., acquisition or significant licensing deal) that values its innovative PREDATOR™ platform and clinical assets substantially above its current market cap. The company's low enterprise value (suggesting net cash) and early positive clinical data, despite financial distress and operational cuts, make it a potential undervalued target for larger biotech players.

Is HOWL Stock Undervalued?

Werewolf Therapeutics faces a critical juncture, having shifted from an independent growth trajectory to actively seeking strategic alternatives, including a potential sale or merger. This fundamental pivot, combined with a drastic 64% workforce reduction and a Nasdaq deficiency notice, severely compromises its previous 10x growth potential as an organic market leader. While its innovative PREDATOR™ platform and the BMS partnership still hold value, and recent clinical data for WTX-124 showed a 30% response rate in advanced melanoma, the company's financial health is precarious due to unsustainable cash burn. The score reflects a significantly heightened risk profile and a shift in the primary driver for a potential 10x return from organic growth to a successful acquisition or lucrative licensing deal, leveraging its distressed valuation (P/B of 0.8x and low EV) and pipeline assets. Analyst price targets (median $7.00, low $4.00) suggest significant upside from current levels, but achieving market leadership independently seems improbable. Score Change Explanation: The score has been significantly adjusted from 8.7/10 (87/100) due to several material negative developments since the 2026-01-14 analysis. Key changes include the company's announcement on Feb 24, 2026, to explore strategic alternatives (sale, merger, asset sales), indicating a major re-evaluation of its standalone viability. This was accompanied by a drastic 64% workforce reduction, impacting operational capacity and R&D. Furthermore, the company received a Nasdaq deficiency notice due to its share price falling below $1.00, raising delisting concerns. Analyst H.C. Wainwright also cut its price target by 60% from $10.00 to $4.00, despite maintaining a "Buy" rating, reflecting a substantial re-assessment of valuation prospects. These events collectively demonstrate a severe deterioration in financial health and a significant impairment to the company's ability to achieve 10x growth through independent market leadership, necessitating a substantial downward revision of its future potential score.

Unlock the full AI analysis for HOWL

Get the complete DVR score, risk analysis, and more

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

HOWL Price Targets & Strategy

12-Month Target

$4.00

Bull Case

$7.00

Bear Case

$0.20

Valuation Basis

Target based on H.C. Wainwright's revised PT after clinical data and strategic review, reflecting asset value in a distressed scenario.

Entry Strategy

Speculative entry near current levels ($0.70-$0.80) for high-risk tolerant investors only, anticipating a favorable outcome from strategic review. Avoid chasing spikes.

Exit Strategy

Take initial profits at $2.00-$3.00, significant profit-taking at $4.00. Stop-loss if price breaks below $0.50.

Portfolio Allocation

1-3% for aggressive risk tolerance only.

Price Targets & Strategy

Upgrade to Premium for price targets and entry/exit strategies

Is HOWL Financially Healthy?

Valuation

P/E Ratio

-0.70

PEG Ratio

0.01

Price/Book

0.80

Price/Sales

42.40

Balance Sheet

Current Ratio

3.87

Cash & Equivalents

$122.80M

Does HOWL Have a Competitive Moat?

Moat Rating

🛡️ Narrow

Moat Trend

Eroding

Moat Sources

2 Identified

Intangible Assets/IPSwitching Costs

The underlying scientific innovation and early clinical data for its platform provide a narrow moat, but its durability is under severe threat from the company's financial instability. Without successful strategic alternatives, the moat risks becoming irrelevant if R&D cannot continue.

Moat Erosion Risks

•Inability to secure sufficient funding to advance pipeline, leading to atrophy of IP
•Competitors developing superior or more advanced conditional immunotherapies
•Failure of ongoing clinical trials to meet endpoints, diminishing asset value

HOWL Competitive Moat Analysis

HOWL Market Intelligence

Sentiment & Insider Activity

Social Sentiment

Bearish, driven by significant share price decline, strategic review news, and workforce reductions. Some speculative retail interest may exist given low price and M&A potential.

Institutional Sentiment

Negative shift, evidenced by H.C. Wainwright's significant price target cut from $10.00 to $4.00, despite maintaining a 'Buy' rating which is likely a re-rating on M&A potential rather than organic growth. The initiation of strategic alternatives suggests institutional pressure or a proactive move to preserve value.

Insider Activity (Form 4)

No specific Form 4 filings (names, titles, shares, values, dates) reported in the last 90 days, indicating no recent insider conviction buys to counter the negative news.

Options Flow

Normal options activity

Earnings Intelligence

Next Earnings

No specific expected date

Surprise Probability

Low

Historical Earnings Pattern

Not applicable given the lack of recent earnings data and the fundamental shift in company trajectory.

Key Metrics to Watch

Cash position and burn rateProgress on strategic alternativesUpdates on pipeline programs (especially WTX-124 and WTX-330)

Competitive Position

Top Competitor

Not specified in research, generally large immuno-oncology players like $MRK or $BMY.

Market Share Trend

Stable

Valuation vs Peers

P/S of 42.4x is extremely high, indicating minimal revenue. P/B of 0.8x suggests it's trading below book value, which for a biotech with a pipeline could be seen as undervalued if assets are worth more than current market perception. EV of ~$4M is very low relative to its market cap, implying significant net cash, making it a potential attractive M&A target based on cash.

Competitive Advantages

•Proprietary PREDATOR™ platform for conditional immunotherapies
•Strategic partnership with Bristol Myers Squibb (BMS)
•Positive clinical signal for WTX-124 in advanced melanoma

Market Intelligence

Get sentiment, earnings intel, and peer analysis with Premium

What Could Drive HOWL Stock Higher?

Near-Term (0-6 months)

•Update on Strategic Alternatives Exploration (Q2 2026)
•Nasdaq Bid Price Compliance Update (before Aug 2026 deadline)

Medium-Term (6-18 months)

•Potential Licensing Deal or Asset Sale Announcement
•Phase 2 data updates for pipeline assets (dependent on retained R&D capacity)

Long-Term (18+ months)

•Successful Merger or Acquisition (if strategic review yields a positive outcome)
•Resumption of organic R&D pipeline progression (highly speculative)

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for HOWL?

✓
Announcement of a specific strategic alternative deal (e.g., acquisition terms, licensing agreements)
✓
Updates on Nasdaq compliance
✓
Any further clinical trial data releases, particularly for WTX-330

Bull Case Analysis

See what could go right with Premium

Competing with HOWL

See how Werewolf Therapeutics Inc compares to related companies

Company	Market Cap	DVR Score	P/E	Revenue	Profit Margin	Rev Growth
Werewolf Therapeutics Inc HOWL	$41.3M	5.1	-0.7	—	0.0%	0.0%
AbbVie Inc ABBV	$403.8B	0.1	171.8	—	—	—	Compare →
Johnson & Johnson JNJ	—	1.0	—	—	—	—	Compare →
Eli Lilly and Co LLY	$965.0B	0.5	52.6	—	—	—	Compare →
Pfizer Inc PFE	$150.6B	0.2	19.4	$62.6B	12.4%	-1.6%	Compare →
UnitedHealth Group Inc UNH	$276.2B	0.3	22.9	$113.7B	2.7%	1181.0%	Compare →

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Werewolf Therapeutics Inc (HOWL)?

As of March 22, 2026, Werewolf Therapeutics Inc has a DVR Score of 5.1 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Werewolf Therapeutics Inc?

Werewolf Therapeutics Inc's market capitalization is approximately $41.3M. The company operates in the Healthcare sector within the Biotechnology industry.

What ticker symbol does Werewolf Therapeutics Inc use?

HOWL is the ticker symbol for Werewolf Therapeutics Inc. The company trades on the NMS.

What is the risk level for HOWL stock?

Our analysis rates Werewolf Therapeutics Inc's overall risk as Aggressive investment. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

What is the P/E ratio of HOWL?

Werewolf Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -0.7. This is below the market average, which could indicate the stock is undervalued or facing headwinds.

Is Werewolf Therapeutics Inc's revenue growing?

Werewolf Therapeutics Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.

Is HOWL stock profitable?

Werewolf Therapeutics Inc has a profit margin of 0.0%. The company is currently unprofitable.

How often is the HOWL DVR analysis updated?

Our AI-powered analysis of Werewolf Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 22, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for HOWL (Werewolf Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.